Binding of C4b-binding Protein to Porin: A Molecular Mechanism of Serum Resistance of Neisseria gonorrhoeae

By Sanjay Ram,* Meabh Cullinane,† Anna M. Blom,‡ Sunita Gulati,* Daniel P. McQuillen,* Brian G. Monks,* Catherine O’Connell,* Ryan Boden,* Christopher Elkins,§ Michael K. Pangburn,‖ Björn Dahlbäck,‡ and Peter A. Rice*

From the *Evans Biomedical Research Center, Boston Medical Center, Boston, Massachusetts 02118; ‡Lund University, Malmö S-20502, Sweden; the §University of North Carolina, Chapel Hill, North Carolina 27599; and the ‖University of Texas Health Sciences Center, Tyler, Texas 75708

Abstract

We screened 29 strains of Neisseria gonorrhoeae and found 16/21 strains that resisted killing by normal human serum and 0/8 serum sensitive strains that bound the complement regulator, C4b-binding protein (C4bp). Microbial surface–bound C4bp demonstrated cofactor activity. We constructed gonococcal strains with hybrid porin (Por) molecules derived from each of the major serogroups (Por1A and Por1B) of N. gonorrhoeae, and showed that the loop 1 of Por1A is required for C4bp binding. Por1B loops 5 and 7 of serum-resistant gonococci together formed a negatively charged C4bp-binding domain. C4bp–Por1B interactions were ionic in nature (inhibited by high salt or by heparin), whereas the C4bp–Por1A bond was hydrophobic. Only recombinant C4bp mutant molecules containing the NH₂-terminal α-chain short consensus repeat (SCR.1) bound to both Por1A and Por1B gonococci, suggesting that SCR.1 contained Por binding sites. C4bp α-chain monomers did not bind gonococci, indicating that the polymeric form of C4bp was required for binding. Using fAb fragments against C4bp SCR.1, C4bp binding to Por1A and Por1B strains was inhibited in a complement-dependent serum bactericidal assay. This resulted in complete killing of these otherwise fully serum resistant strains in only 10% normal serum, underscoring the importance of C4bp in mediating gonococcal serum resistance.

Key words: Neisseria gonorrhoeae • C4b-binding protein • porin • serum resistance • short consensus repeat

Introduction

Neisseria gonorrhoeae is one of two bacterial pathogens involved in the majority of cases of sexually transmitted genitai infection and pelvic inflammatory disease (PID);¹ the other is Chlamydia trachomatis. Gonococci that cause symptomatic local inflammation (PID) usually are sensitive to killing by nonimmune normal human serum (NHS) in vitro (1). Complement component C3 is present in functional amounts at the cervical level (2, 3), is synthesized in the endometrial glandular epithelium (4, 5), and binds to gonococci in vivo (6). Serum-sensitive (SS) gonococci can abrogate killing by NHS by adding sialic acid to their lipooligosaccharide (LOS [7–11]), which permits direct binding of the complement regulatory protein factor H to sialylated LOS (12). This is termed unstable serum resistance (SR). In vivo, gonococci appear to be heterogeneously sialylated (6, 13). Disseminated bloodstream infection with gonococci (DGI) often occurs in the absence of local genital inflammation and is caused predominantly by gonococci that resist killing by NHS independent of sialylation, termed stable serum resistance (14). These isolates sometimes lack the LOS acceptor site for sialic acid (15), or may not completely sialylate LOS for reasons that remain unclear. Commonly they also express the gonococcal major outer membrane protein serotype porin (Por)1A (16, 17). Gonococcal Por comprises 60% of the outer membrane protein content (18). Por is a
34–35-kD protein comprising 8 transmembrane loops (16 membrane spanning segments) whose native configuration is a homogenous trimer that functions as a selective anion channel (18, 19). Por is an allelic protein consisting of two main isoforms, Por1A and Por1B (17, 20). There is moderate antigenic variation between the isoforms, which subdivides them into serotypes or serovars (21–23). Por1A gonococci frequently cause disseminated disease, whereas Por1B strains usually cause local urogenital disease and PID in women (16, 17, 20). We have recently shown that Por1A isolates resist killing by directly binding factor H, a regulator of the alternative pathway of complement, to the surface exposed loop 5 of Por1A (24).

Although the alternative pathway is important in C3 deposition on the gonococcal surface, the classical pathway of complement is required to initiate this deposition and resultant killing (25). A key soluble phase classical pathway regulatory protein is C4b-binding protein (C4bp), which is present in human plasma at concentrations of 200–250 μg/ml. C4bp is a cofactor in factor I–mediated cleavage of C4b to C4d, and accelerates dissociation of C2a from the classical pathway C3 convertase (C4b, 2a), thereby down-regulating the classical pathway (26–30). C4bp (Mr = 570 kD) is composed of seven identical 70-kD subunits (α-chains) linked by disulfide bridges (30, 31). When visualized by electron microscopy, it appears as a spider-like structure with seven elongated tentacles (α-chains) extending from a central, ring-like core (32, 33). The NH2-terminal 491 (of a total of 549) residues of each α-chain are organized into eight short consensus repeat (SCR) domains, and each SCR is comprised of ~60 amino acids. A patch of positively charged residues at the interface between the first and second NH2-terminal SCRs plays an important role in the interaction between C4bp and C4b as well as heparin (34). C4bp also contains a 45-kD subunit (β-chain), organized into three SCRs, which is attached to the central core region of the molecule by a disulfide bond (35). Three isoforms with different subunit compositions have been identified in human plasma; the major isoform is comprised of seven α-chains and one β-chain (α7β1); the remaining isoforms are α7β0 and α6β1 (36).

Many isolates of *Streptococcus pyogenes* have been reported to bind C4bp, which may contribute to pathogenicity (37). Binding of C4bp occurs through the NH2-terminal highly variable region of several members of the M protein family present in this species (38). In addition, C4bp binding has been demonstrated to all clinical isolates of *Bordetella pertussis* expressing the filamentous hemagglutinin (39). Because the classical pathway is crucial in initiating complement deposition on gonococci (25), regulation of this pathway could provide a very efficient means for the bacteria to evade the bactericidal action of serum at an early stage of complement activation. In this work, we detail the interactions between C4bp and gonococcal Por, and demonstrate the function of C4bp in mediating stable SR (SR not mediated by LOS sialylation).

### Materials and Methods

#### Bacterial Strains and Plasmids

29 strains of *N. gonorrhoeae* were screened for binding to C4bp; these are listed in Table I. Strain FA6616, containing the MS11 Por molecule reintroduced into an MS11 background using plasmid pUNCH61 (40), was used in this study, and for convenience will be referred to as MS11 hereafter. Bacteria grown on chocolate agar supplemented with Isovitalex equivalent in 5% CO2 for 10 to 11 h (41) were suspended in HBSS containing 0.15 mM CaCl2 and 1 mM MgCl2 (HBSS2+) in C4bp binding assays. Alternatively, bacteria were harvested from chocolate agar plates after overnight growth and grown in gonococcal liquid media (41). Results of C4bp binding were equivalent when strains were grown in either media. Plasmids

#### Table I. C4bp Binding and Phenotype of 29 Strains of Neisseria gonorrhoeae

| Strain (reference) | Phenotype | C4bp binding |
|--------------------|-----------|--------------|
| Por1A strains      |           |              |
| 15253 (78, 79)     | SR        | +            |
| 401082 (24)        | SR        | +            |
| 339063 (24)        | SR        | +            |
| DGI isolate 1 (14) | SR        | +            |
| 179008 (24)        | SR        | +            |
| FA19 (80, 81)      | SR        | +            |
| 442089 (24)        | SR        | +            |
| 273043 (24)        | SR        | +            |
| UU1 (46, 47)       | SS        | –            |
| 374073 (24)        | SR        | –            |
| DGI isolate 56 (this study) | SR | – |

| Por1B strains      |           |              |
| FA1090 (82)        | SR        | +            |
| 156001 (24)        | SR        | +            |
| 1291 (83)          | SR        | +            |
| BMC-1 (84)         | SR        | +            |
| FA6616* (40)       | SR        | +            |
| WG (14)            | SR        | +            |
| 422083 (24)        | SR        | –            |
| 252 (24)           | SR        | –            |
| 336062 (24)        | SR        | –            |
| DGI isolate 40 (14)| SR        | +            |
| DGI isolate 17 (14)| SR        | +            |
| 398079 (24)        | SS        | –            |
| 256036 (24)        | SS        | –            |
| 255034 (24)        | SS        | –            |
| F62 (85)           | SS        | –            |
| 24-1 (61)          | SS        | –            |
| Pgh 3-2 (46, 47)   | SS        | –            |
| 150002 (24)        | SS        | –            |

*Referred to as MS11 in this study.*

282 Gonococcal Serum Resistance Is Mediated by C4b Binding to Porin
pUNCH61 and pUNCH62 contained the por1B and por1A genes of strains MS11 and FA19, respectively, plus ~1 kb of gonococcal DNA 3′ to the por gene, containing a chloramphenicol-resistance marker (Cm \(^{\text{R}}\) \([40, 42]\)). Strains MS11 and FA19 are resistant to killing (SK) by 33% nonimmune NHS.

For MS11 loop 5 or 6 with F62 loops 5 or 6, respectively, and vice versa (44). To construct each mutation, we performed two separate PCR reactions with the primer pairs listed in Table III. De

**Por Mutagenesis.** We used overlap extension PCR to replace MS11 loop 5 or 6 with F62 loops 5 or 6, respectively, and vice versa (44). To construct each mutation, we performed two separate PCR reactions with the primer pairs listed in Table III. De
sure that the desired mutation had been obtained in F62, entire por genes of mAb 1F5-positive clones were amplified using primers PorI and PorII, and DNA sequencing was performed at the DNA core facility at Boston University School of Medicine using an Applied Biosystems automated sequencer.

In an effort to obtain a strain containing loop 1 of FA19 and loops 2–8 of F62, we cloned the chloramphenicol-resistance marker into the HindII site of gonococcal DNA 5' to the FA19 por1A gene in pUNCH 30 (45), and used this plasmid, designated pBUMC2, to transform F62. Attempts to create a hybrid Por molecule containing the NH2 terminus of the FA19 Por and the COOH terminus of F62 Por were not successful; therefore, we attempted to construct a hybrid Por molecule that contained loop 1 from strain FA19 and loops 2–8 from another gonococcal strain, UU1 (46, 47). UU1 is a Por1A strain that is SS and does not bind C4bp. We introduced a SpeI site 2 bp 3' to the UU1 por gene by PCR using PorI as the forward primer and 5'-GCG ACT AGT ATT AGA ATT TGT GGC GCAG-3' as the reverse primer. Then, using the QuikChange™ site-directed mutagenesis kit (Stratagene), a SpeI site was similarly introduced 3' to the FA19 por1A gene in pUNCH62 using primer 5'-GAC AGA CTA GTT GTT GAT ACC GAT-3' and its complementary primer. A new construct was made by ligating the BsiI-SpeI fragment of UU1 into pUNCH62, which had been predigested with the same enzymes. The resultant plasmid, pBUMC3, that contained hybrid Por molecule FA19loop1UU1loop2–8 was used to attempt transformation of strains F62 and UU1 (see Results: C4bp Binding Region in Por1A).

Sera and Complement Reagents. Nonimmune NHS was obtained from 10 healthy volunteers with no prior history of neisserial infection. Sera were aliquoted and stored at −70°C until further use. In some experiments, NHS was incubated at 56°C for 30 min to yield heat-inactivated serum (HIS). NHS was adsorbed against glutaraldehyde-fixed bacteria (strain F62pMS11; Por influences IgM Binding to Gonococci). Purified C4b was obtained from Advanced Research Technologies. C4bp that was either complexed to or devoid of protein S (a component of the protein C anticoagulation system) was purified from human plasma using previously described methods (48).

*Recombinant C4bp Mutant Proteins.* Recombinant human C4bp and seven polymeric rC4bp mutant molecules lacking individual SCRs were constructed by an overlapping PCR technique that used as a template full-length cDNA coding for the α-chain of human C4bp (49) cloned in vector pcDNA3 (Invitrogen). The amino acids deleted (represented as deletions of SCRs 1 to 7 deleted sequentially) in each construct and sequences of primers used are listed in Table IV. The final PCR product was cloned into HindII and NotI sites in vector pcDNA3 and used as the transfecting construct. Nucleotide sequences of all mutations were determined by automated DNA sequencing (PerkinElmer).

Human kidney 293 cells (American Type Culture Collection catalog no. 1573-CRL) were transfected with individual C4bp constructs, and the expressed proteins, with the exception of rC4bpΔSCR1, were purified by affinity chromatography using mAb 104 (specific for C4bp SCR1) as described previously (50). rC4bpΔSCR1 was affinity purified using mAb 67 (specific for C4bp SCR 4; reference 51).

C4bp α-chain monomers containing all eight SCRs were constructed by introducing the STOP codon after SCR 8 using primer 5'-CCC AAG TGT GAG TGG TAG ACC CCC GAA GGC TGT-3' (stop codon indicated in bold). Ab. Transformants were screened using serotyping mAbs against gonococcal Por (21). These included mAb 2F12 (specific for FA19 Por loop 1), 9D2 (central region of FA19 Por), 1F5 (MS11 Por loop 1), and 3C8 (loop 5 of MS11 Por). These mAbs were used in colony blotting experiments or in whole cell ELISA at a dilution of 1 μg/ml in PBS-0.05% Tween 20.

Anti-C4bp mAb (Quidel Corp.) was used in flow cytometry experiments (see below) at a concentration of 20 μg/ml in HBSS+. In some experiments, a sheep polyclonal Ab against human C4bp (Biodiagnostic International) was used in flow cytometry experiments at a dilution of 1:50 in HBSS+. mAbs specific for C4c and C4d were purchased from Quidel Corp., and used in flow cytometry experiments at a dilution of 20 μg/ml in HBSS+. C4c and C4d are the fragments of C4b generated when the enzyme factor I acts together with its cofactor C4bp to cleave C4b. C3 bound to bacteria was detected using an IgG fraction of goat anti–human C3 (Organon Teknika-Cappel) at a concentration of 100 μg/ml. C5b–9 on the bacterial surface was detected by flow cytometry using an IgG fraction of rabbit anti–human SC5b–9 neoantigen (Advanced Research Technologies) at a 1:50 dilution in HBSS+. To identify the region in C4bp that bound gonococcal Por, we used five mAbs directed against C4bp SCR 1 to 2 (mAb 104, mAb 102, mAb 96, mAb 92, and mAb 70) and mAb 67 (specific for SCR 4 of the α-chain of C4bp; reference 51), in experiments to attempt to inhibit binding of C4bp to the bacterial surface. The functional effects of abrogating C4bp bind-

| Table IV. Primers Used for Construction of Recombinant Human C4bp Deletion Mutant Molecules |
|-----------------------------------------------|
| rC4bp protein | Amino acids deleted | Sense primer (5'→3')* |
|----------------|-------------------|----------------------|
| rC4bp ΔSCR1 | N1 to Y62 | CCT GCT GTT CTT GGC AAA CGA TGC AGA CAC |
| rC4bp ΔSCR2 | K63 to I124 | ACC TCC TGT ATC TGC AGC TGG TAG CCT |
| rC4bp ΔSCR3 | V125 to K188 | CCA GAA TGG GAA ATT ATC ACC TGG CGC AGG |
| rC4bp ΔSCR4 | K188 to N249 | CCT CTC ACC TGT GAA AAT AGT TGT ATT AAT |
| rC4bp ΔSCR5 | N 249 to A314 | CCT GCT TGT GAG CCC TTA TGT TGC CCT GAA |
| rC4bp ΔSCR6 | A314 to G375 | TAC CAA GGA TGT GAG GAC ATT TGC AAT TTT |
| rC4bp ΔSCR7 | D376 to K433 | ACA CCA TCA TGT GGA GCT CTT TGC CGG AAA |

*The sense primer listed above was used in conjunction with primer T7, and its complimentary antisense counterpart was used with primer Sp6 included in the polylinker sequence of the vector.*
ing to the bacterial surface were studied by using fAb fragments of mAb 104 to avoid confounding by possible Fc related effects of the inhibiting Ab; fAb fragments of mAb 67 (specific for C4bp SCR 4), shown not to influence C4bp binding to bacteria, were used as controls. fAb fragments were generated from mAb 104 by digestion with immobilized papain using a kit (Pierce Chemical Co.) according to the manufacturer's instructions. We observed that papain digestion of mAb 67 did not yield the desired \( \sim 50-kD \) fAb fragment, but instead a 110-kD (possibly \( \text{F(ab')}_2 \)) fragment. However, digestion with immobilized papain yielded 50-kD fragments that retained the capacity to bind C4bp by ELISA (see below).

**Flow Cytometry.** Flow cytometry was used to quantify IgM, C4bp, C4c, C4d, C3, and C5b-9 binding to the bacterial surface, using methods described previously (12). In brief, \( 10^8 \) bacteria suspended in HBSS \( + \) were incubated either with NHS, purified C4bp, or rC4bp deletion mutant molecules (quantity specified in each experiment, final volume of reaction mixture 100 \( \mu \)l), followed by detection of the indicated component using the specified primary and appropriate FITC-labeled secondary conjugate (Sigma-Aldrich). In some experiments, inhibition of C4bp binding was attempted using high salt conditions, heparin, pure C4b, anti-C4bp mAbs, or their fAb fragments (see above). Conditions are specified for each experiment.

**Bactericidal Testing.** Serum bactericidal testing was performed as described previously (41). In some experiments, C4bp binding to the bacterial surface was abrogated using 25 \( \mu \)g fAb 104. This represents an \( \sim 70\text{-fold} \) molar excess of fAb 104 over C4bp in a bactericidal assay using 10% NHS. In bactericidal experiments to demonstrate that enhanced Ab binding was responsible for the serum sensitive phenotype of F62_{porB\_MS11}, organisms were incubated with either 15 \( \mu \)l HIS (antibody source) or buffer (control), and NHS adsorbed against glutaraldehyde-fixed F62_{porB\_MS11} was used as a source of complement. The final volume of the bactericidal reaction mixture in every experiment was maintained at 150 \( \mu \)l.

**ELISA.** To determine whether fAb fragments of mAb 67 retained the ability to bind C4bp, we coated ELISA plates with either 10 \( \mu \)g/ml mAb 67 or the derived fAb fragment in bicarbonate buffer pH 9.6 for 2 h at 37°C, followed by blocking with 1% porcine gelatin (Sigma-Aldrich) for 30 min at 37°C. Plates were then washed twice with PBS-0.05% Tween 20, and cell culture supernatant containing rC4bp was applied to each well for 1 h at 37°C. After washing with PBS-Tween, bound C4bp was detected using a sheep polyclonal anti-C4bp (Biodesign) and alkaline phosphatase–conjugated anti–sheep IgG (Sigma-Aldrich). The OD at 410nm obtained with binding of rC4bp to the fAb fragment was compared with the OD at 410nm obtained with rC4bp binding to the intact mAb.

**Results**

**C4bp Binding Correlates with Serum Resistance**

We screened 29 clinical and laboratory gonococcal isolates (Table I) for C4bp binding using flow cytometry. Strains were incubated with 10% NHS for 30 min, followed by detection with an anti-C4bp mAb. The geometric mean fluorescence intensity of C4bp binding did not differ among strains that bound C4bp, when tested under similar assay conditions (representative positive and negative tracings are shown in Fig. 2 by F62_{porB\_FA19} and F62_{porB\_FA2}, respectively). Resistance of each of the 29 strains to killing by 10% NHS is indicated as phenotype in Table I. 11 strains belonged to the Por1A serogroup; the remaining 18 were Por1B. 10 of 11 Por1A strains were resistant to killing by 10% NHS (SR). 8 of the 10 SR Por1A strains bound C4bp; the only SS Por1A strain that was tested did not bind C4bp. 11 of the 18 Por1B strains were SR, and 8 of these strains bound C4bp; no SS Por1B strains bound C4bp. A strong correlation was observed between C4bp binding and a SR phenotype (\( P < 0.0001 \) by Fisher's exact test).

We noted that all Por1B strains that bound C4bp belonged to closely related serovars, and most bound the serotyping mAb 3C8 (21) that is specific for loop 5 of certain Por1B strains (52). This suggested the possibility that the central region of Por1B might be important in C4bp binding.

**C4bp Binds Directly to Gonococci; Protein S Does Not Influence C4bp Binding**

The major isoform of C4bp found in blood is seven \( \alpha \)-chains and one \( \beta \)-chain (\( \alpha 7\beta1 \)), and virtually all C4bp (\( \alpha 7\beta1 \)) is complexed with protein S, a component of the protein C anticoagulation system (48). To consider a possible effect of protein S in influencing C4bp binding to gonococci, we compared the binding of 2.5 \( \mu \)g of pure C4bp free of protein S and an equivalent amount of C4bp coupled to protein S to strains FA19 (Por1A) and MS11 (Por1B). The amount of C4bp bound to the two strains under each condition of incubation was similar (data not shown), thereby suggesting that C4bp binding is not influenced by protein S.

**C4bp Bound to Gonococci Has Cofactor Function**

C4bp regulates classical complement pathway activation by serving as a cofactor in the inactivation of C4b by factor I, and yields the C4 fragments C4d (which remains bound to the bacterial surface) and C4c (released into solution). Cofactor function of C4bp was assessed using mAbs directed against C4c and C4d. mAb against C4d is specific for the parent molecule C4b as well as the fragment C4d, whereas mAb against C4c recognizes C4b and C4c, but not C4d. Therefore, cofactor activity will not alter the amount of C4 measured on the bacterial surface by the mAb against C4d, but will decrease the amount of C4 bound to the organism measured by mAb against C4c, resulting in a higher C4d/C4c ratio (53). We measured C4c and C4d on strains incubated in 20% NHS for 30 min at 37°C. We used strain F62 (SS, Por1B, does not bind C4bp), FA19 (SR, Por1A, binds C4bp), and MS11 (relatively SR, Por1B, binds C4bp). We observed that both C4bp-binding strains showed a higher C4d/C4c ratio (4 for MS11 and 5.4 for FA19) than that observed with strain F62 (1.17; Fig. 1). Thus, C4bp that binds to the bacterial surface exhibits cofactor activity.

**Defining Por as the Acceptor for C4bp**

We next examined if Por1A was the acceptor molecule for C4bp by replacing the Por1B of F62 (does not bind C4bp) with the Por1A molecule of strain FA19 (binds...
Gonococcal Serum Resistance Is Mediated by C4b Binding to Porin

C4bp) using plasmid pUNCH62 (40). Colony lifts of transformants that resulted from homologous recombination were screened using serotyping mAbs 2F12 and 9D2 (21) that are specific for the NH2-terminal and central region of FA19 Por, respectively (42, 54). Clones that reacted with both mAbs were deemed to have acquired most of the FA19 Por1A molecule in their F62 background. The presence of the entire FA19 Por molecule was confirmed by DNA sequencing. One such isogenic mutant, designated F62PorFA19, bound C4bp in a flow cytometry assay (Fig. 2, left), and demonstrated 100% survival in 10% NHS (SR), akin to the parent strain FA19.

Similarly, we used plasmid pUNCH61 (40) to replace the Por molecule of F62 with MS11 Por. Transformants were screened using mAbs 1F5 (specific for MS11 loop 1) and 3C8 (specific for the central region of MS11, but not F62, Por). Again, the presence of the entire MS11 Por molecule was confirmed by DNA sequencing. One such isogenic mutant, designated F62PorFA19, bound C4bp in a flow cytometry assay (Fig. 2, right), and demonstrated 100% survival in 10% NHS (SR), akin to the parent strain FA19.

Defining Por Loops Required for C4bp Binding

C4bp Binding Region in Por1A. Transformation of F62 with plasmid pUNCH62 (40) produced clones with hybrid Por1A/1B molecules that were recognized by mAb 9D2 (recognizes a central region of FA19 Por) but not mAb 2F12 (specific for FA19 loop 1), indicating that a recombination had occurred between loop 1 and loop 5. Two classes of hybrids were identified, one with F62loop1

FA19loop2–8, and the other with F62loop1–FA19loop5–8 (Fig. 3). Neither class of hybrid bound C4bp, suggesting that the loop 1 of FA19 Por1A was essential for C4bp binding.

We attempted to construct a hybrid Por in an F62 background that contained the NH2 terminus of FA19 Por (loop 1), and the COOH terminus of F62, to test if such a hybrid bound C4bp, thereby proving that loop 1 of FA19 contained the C4bp binding region exclusively. We were unsuccessful having used the following strategies. The first strategy we used was to transform F62 with pBUMC2 (see Materials and Methods). A recombinational event that occurred within the por gene would have resulted in a hybrid containing the NH2 terminus of FA19 and the COOH term-

Figure 2. Por1A of FA19 and Por1B of MS11 are the acceptor molecules for C4bp. To demonstrate this for FA19 Por1A, we used pUNCH62 (reference 40) to replace F62 Por1B (C4bp nonbinder) with FA19 Por1A. The resultant strain, termed F62PorFA19, bound C4bp in a flow cytometry assay when incubated with 10% NHS (left), indicating that FA19 Por1A was an acceptor molecule for C4bp. Similarly, using plasmid pUNCH61 (reference 40) we replaced F62 Por1B with MS11 Por1B, and observed that the isogenic mutant F62PorMS11 bound C4bp (right), indicating that MS11 Por1B was an acceptor molecule for C4bp.
minus of F62. Approximately 100 chloramphenicol-resistant colonies (the result of two separate transformation experiments) were screened using mAb 2F12 (specific for FA19 Por loop 1), but none of the clones reacted with this mAb. The second strategy was to construct a plasmid derived from pUNCH62 that contained loop 1 from FA19 and loops 2–8 of a C4bp-nonbinding Por1B molecule by cloning the BbsI-XbaI fragment of pBUMC1 into the corresponding region of pUNCH62. This plasmid coded for a Por hybrid FA19loop1F62loop2–7MS11loop8. Attempts to transform F62 with this plasmid also did not yield clones that contained the desired hybrid. These results strongly suggested that formation of this hybrid resulted in a lethal mutation. Finally, we attempted to construct a more “physiologic” hybrid Por molecule containing FA19 loop 1 and UU1 loop 2–8. Plasmid pBUMC3, containing the Por hybrid FA19loop1UU1loop2–8, was constructed and used to transform F62, as well as UU1. However, none of ~50 colonies from each transformation attempt reacted with the FA19 loop 1 specific mAb 2F12, suggesting that the desired hybrid had not been obtained. We also observed that rates of transformation in all the above experiments were significantly lower than with control plasmids pUNCH61 and pUNCH62, again strongly suggesting that a hybrid containing loop 1 from FA19 and loops 2 through 8 from either F62 or UU1 were lethal to gonococci.

The results of the above experiments demonstrate that FA19 loop 1 is required for C4bp binding. However, we cannot conclude that the presence of this loop alone is sufficient for C4bp binding.

C4bp Binding Region in Por1B. The C4bp binding region in MS11 Por1B was mapped using 12 strains containing F62/MS11 hybrid Por molecules, as shown in Fig. 4. Transformation of strain F62 with plasmid pUNCH61 resulted in strains with hybrid Por molecules F62loop1MS11loop2–8 and F62loop1–4MS11loop5–8. F62 sequence is indicated by black bars; MS11 sequence is represented by hatched bars. Both hybrids bound C4bp, suggesting that the C4bp binding region in MS11 lay in a region encompassed by loops 5–8. The BbsI-BglI fragment of F62 was cloned into pUNCH61 to obtain pBUMC1 and this plasmid was used to transform F62. This yielded a gonococcal strain with hybrid Por molecule MS11loop1F62loop2–7MS11loop1–8, which did not bind C4bp, thus eliminating MS11 loop 8 as the C4bp binding loop. Using overlap extension PCR or site-directed mutagenesis on pBUMC1, we mutated loops 5, 6, or 7 either individually or in combination and then transformed F62. We noted that only hybrid Por molecules that contained both MS11 loop 5 and loop 7 bound C4bp. To further demonstrate the absolute requirement of MS11 loops 5 and 7, we mutated MS11 loops 5, 6, and 7 individually in pUNCH61 to resemble the corresponding F62 loop, and then transformed F62. Mutations of loop 5 (MS11loop1F62loop2–7MS11loop8) and loop 7 (MS11loop1–5F62loop2–7MS11loop8) resulted in complete abrogation of C4bp binding, whereas mutating loop 6 (MS11loop1–4F62loop2–7MS11loop8) did not influence C4bp binding. Collectively, these data suggest that MS11 loops 5 and 7 together participate in forming a C4bp-binding domain.
region of MS11 Por; reference 42), but not mAb 1F5 (specific for MS11 loop 1; reference 42), indicating again that recombination had occurred between loop 1 and loop 5. Two classes of hybrids were identified, one with F62loop1MS11loop2–8 and F62loop1–4MS11loop5–8. Both of these hybrids bound C4bp, suggesting that the C4bp binding domain in Por1B lay in the COOH-terminal half of the molecule (Fig. 4).

We replaced the BbsI-BglII fragment of pUNCH61 with the corresponding BbsI-BglII fragment from the F62 Por1B molecule to obtain plasmid pBUMC1 that contained a hybrid Por sequence MS11loop1-F62loop2–4MS11loop5–8 (Fig. 4). Gonococcal colonies were screened using mAb 1F5 (specific for MS11 loop 1) to identify clones that were likely to contain the constructed hybrid molecule. DNA sequencing of the por gene confirmed that the gonococcal clones contained the desired hybrid molecule. This hybrid did not bind C4bp, thus narrowing down C4bp binding to a region encompassed by MS11 loops 5–7. Using overlap extension PCR or site-directed mutagenesis, we mutated the exposed regions of loops 5, 6, and 7 individually in pBUMC1 to reinsert MS11 sequence back into this region of the F62 Por. Individual mutations of loops 5, 6, and 7 did not restore C4bp binding. We next studied the effects of mutating the combinations of either loops 5 and 6, loops 6 and 7, or loops 5 and 7 together in pBUMC1 to simulate MS11 loops. Only the presence of MS11 loop 5 and 7 simultaneously resulted in C4bp binding (as demonstrated by the hybrid MS11loop1-F62loop5 MS11loop5–8 and MS11loop1–6F62loop6MS11loop5–8; Fig. 4), suggesting that these two loops together participated in formation of a C4bp-binding domain (indicated by the gray shaded boxes in Fig. 4).

To further demonstrate the necessity of MS11 Por loops 5 and 7, but not loop 6, for C4bp binding, we mutated each of these loops individually in pUNCH61 (contains the entire MS11 por sequence), to yield hybrid Por molecules that differed from MS11 only at loops 5, 6, or 7, which were mutated to duplicate these regions in F62. Substitution of loops 5 and 7 separately (hybrids MS11loop1–4F62loop5 MS11loop5–8 and MS11loop1–6F62loop6MS11loop5–8, respectively; Fig. 4), but not loop 6 (hybrid MS11loop1–6F62loop6 MS11loop5–8), completely abrogated C4bp binding (Fig. 4). Collectively, these data suggest that MS11 loops 5 and 7 participate in the formation of a C4bp binding domain.

Enhanced IgM Binding to F62PorMS11: Por Influences IgM Binding to Gonococi

Serum bactericidal testing revealed that F62PorMS11 was fully susceptible (0% survival) to the killing action of 10% NHS, despite its ability to bind C4bp. In contrast, hybrid F62loop1–4MS11loop5–8 that differed from F62PorMS11 only at Por loop 1 was fully resistant to 10% NHS. We compared the Ig and complement (C3 and C5b-9) binding properties of F62PorMS11 with F62loop1–4MS11loop5–8 and F62 to explain the apparent paradox between the ability of F62PorMS11 to bind C4bp and its SS phenotype. We observed that F62PorMS11 bound two- and fourfold more IgM than parent strain F62 and mutant strain F62loop1MS11loop2–8, respectively (Fig. 5). The amount of C3 and C5b–9 bound to F62PorMS11 was twofold more than that observed with F62loop1–4MS11loop5–8, and fivefold less than that detected on F62 (Fig. 5). IgG binding to the three strains was low (geometric mean fluorescence <10 for all strains), making meaningful interstrain comparisons difficult. To demonstrate that Ig was responsible for killing F62PorMS11, we adsorbed NHS against glutaraldehyde-fixed bacteria (F62PorMS11) at 4°C to deplete NHS of bacteria-specific antibody (41), which abrogated bactericidal activity against this strain (100% survival observed). The addition of heat-inactivated NHS to a final concentration of 10%, which acted as an antibody source, restored 99% killing of F62PorMS11. MS11 and F62loop1–4MS11loop5–8 showed 100% survival (remained SR) under both bactericidal assay conditions, and served as controls for this experiment. Similarly, hybrid F62loop1–4MS11loop5–8, which was also found to be SS despite binding C4bp, bound levels of IgM that were simi-
lar to those observed with F62PordMS11. These data provide evidence that the Por molecule, in addition to determining C4bp binding, may also dictate levels of IgM binding to the gonococcal surface, and that the two factors may inter-
act to determine bacterial killing.

Characterization of the bonds between C4bp and Por. The effects of ionic strength and the influence of two known ligands of C4bp (C4b and heparin) on C4bp–Por interactions were studied. C4b, when added in a 60-fold molar excess of C4bp, decreased binding of C4bp to MS11 by 50% (Fig. 6 A). In the presence of 125 units of heparin (Fig. 6 B) or 575 mM NaCl (Fig. 6 C), binding of C4bp to MS11 was decreased by >90% and ~85%, respectively. None of these three conditions influenced the binding of C4bp to Por1A strain FA19. Based on these observations, it may be concluded that the C4bp–Por1B bond is ionic in nature, and that the binding site for Por1B in C4bp may reside at or very near binding sites in C4bp for heparin and C4b, which has been mapped to the interface between SCRs 1 and 2 (34). This region also overlaps the binding site for streptococcal M proteins (55). In contrast, the Por1A–C4bp interaction could be hydrophobic, and is not influenced by ionic strength of buffers or heparin.

C4bp SCR1 contains Por1A as well as Por1B binding sites. We determined that the binding site for gonococcal Por1A as well as Por1B resided in the α-chain of C4bp because recombinant polymeric human C4bp (rC4bp) that lacked the β-chain bound to FA19 as well as MS11 using flow cytometry. Native C4bp purified from human serum (containing the β-chain) bound to these two strains with similar fluorescent intensity as rC4bp (data not shown). Neither type of C4bp bound to strain F62. To determine the specific SCR(s) of C4bp that bound gonococci, we used rC4bp molecules expressed in human kidney cell line 293 that lacked individual α-chain SCRs and studied their binding to strains FA19 and MS11. rC4bp mutant molecule that lacked SCR1 bound neither FA19 or MS11, suggesting that SCR1 was required for binding to both gonococcal Por types (Fig. 7 A). Deletion of other domains individually had no significant impact on C4bp binding to gonococci. Further proof that SCR1 bound to both Por1A (strain FA19) and Por1B (strain MS11) was evidenced by showing that five mAbs directed against the NH2-terminal end of the α-chain of C4bp (mAb 70, mAb 92, mAb 96, mAb 102, and mAb 104; reference 51) each were able to completely inhibit C4bp binding to both strains (as an example, mAb 104 inhibition of C4bp binding shown in Fig. 7 B). mAb 67, directed against C4bp α-chain SCR4 (51), did not influence C4bp binding to either strain and served as a control for this experiment (Fig. 7 B).

To determine if the organization of the heptameric α-chain structure of the C4bp molecule was required for C4bp binding to Por, we studied binding of 5 μg of recombinant monomeric α-chain of C4bp that contained all eight α-chain SCRs, to strains FA19 and MS11 in a flow cytometry assay. The monomeric molecule did not bind to either Por, indicating a requirement for the polymeric form of C4bp α-chains to bind gonococcal Por (data not shown). Both mAb 67 as well as polyclonal anti-C4bp (Biodesign), which were used as detection Abs in flow cy-
tometry, were capable of binding either monomeric or polymeric C4bp (data not shown).

Figure 6. Characterization of Por–C4bp bonds. The influence of C4b, heparin and high-ionic strength on Por–C4bp binding was studied by flow cytometry. C4b, when added to C4bp in a 60-fold molar excess, inhibited C4bp binding to MS11 (Por1B) by 40% (A). 125 units of heparin completely inhibited C4bp binding to MS11 (B), and 575 mM NaCl reduced C4bp binding to MS11 by >80% (C). None of the above conditions influenced C4bp binding to FA19 (Por1A). To minimize bacterial lysis in these experiments, organisms were first fixed with 1% paraformaldehyde. Fixing gonococci before incubation with C4bp did not alter C4bp binding properties.
Abrogating C4bp binding to gonococci results in complete bacterial killing. We have shown that C4bp that binds directly to the bacterial surface exhibits cofactor activity (see above). The ability to kill SR gonococci by selectively inhibiting C4bp binding would provide more definitive proof of the biological importance of this molecule. We prepared fAb fragments from mAb 104, and demonstrated that fAb 104, when added to NHS, completely inhibited C4bp binding to FA19 as well as to MS11 in a flow cytometry assay (Fig. 8 A). fAb 67 was used as a control, and did not influence C4bp binding to gonococci (not shown). We confirmed that fAb 67 retained 60% of the ability of mAb 67 to bind C4bp in ELISA (data not shown). Abrogating C4bp binding with fAb 104 resulted in a decreased C4d/C4c ratio, as well as enhanced C5b-9 insertion in the bacterial membrane (Table V), demonstrating that classical pathway regulatory activity was lost when C4bp binding to FA19 and MS11 was inhibited. We also performed a bacterial assay including fAb 104 in the reaction mixture (molar ratio of fAb 104 to C4bp in the reaction mixture ~70) to divert C4bp away from these bacterial surfaces. We observed complete killing of strain FA19, and >80% killing of MS11 at t = 30 min (Fig. 8 B). fAb 67, used as a control, showed no effect. Kinetics of bacterial killing showed an almost linear and steady decrease in bacterial viability over time, with almost complete killing observed at 30 min (Fig. 8 C) when C4bp binding was abrogated. The importance of C4bp in contributing to serum resistance of FA19 and MS11 can be gauged from the fact that both strains resist bactericidal activity of up to 33% NHS (24); FA19 resists killing of up to 66% NHS.

**Discussion**

Complement is present in cervical secretions (3), and evasion of complement-mediated killing is vital for survival of gonococci. *N. gonorrhoeae* have evolved intricate mechanisms to evade complement. All gonococcal strains initially recovered from the human genital tract are resistant to the bactericidal action of NHS; strains that lose this property upon serial subculture (56) are termed unstably serum resistant, and this phenotype is facilitated by binding of factor H to sialic acid attached to LOS (12).

Strains that remain resistant after subculture are termed SR strains. Prior work in our laboratory has also defined factor H binding to the loop 5 of Por1A strains as a probable mechanism of stable serum resistance (24). In these studies, we have shown C4bp binding to Por1A as an additional mechanism whereby Por1A strains can evade complement. However, Por1B isolates form a significant proportion of gonococcal isolates worldwide (57–59). Por1B strains are generally non- or weak binders of factor H, and must therefore evade complement by other mechanisms. This study defines C4bp binding to Por1B as an important mechanism of stable serum resistance in gonococci that belong to this serogroup.

We have shown that a strong correlation between C4bp binding and stable serum resistance in gonococci. None of the serum sensitive strains recovered from persons with gonococcal disease that we tested were C4bp binders (Table I). However, during the course of our studies, we observed that introduction of the entire MS11 Por1B-9 into an F62 background (F62PorMS11) resulted in C4bp binding as expected (Fig. 1), but unexpectedly did not convert the transformant to an SS phenotype. However, hybrid Por
molecule F62_loop1MS11loop2–8 moved into the same F62 background also bound the same amount of C4bp, but was fully SR. Almost fourfold higher levels of IgM bound to F62PorMS11 compared with F62 loop1MS11loop2–8 (Fig. 5). These data provide evidence that, in addition to binding C4bp, the Por molecule may also dictate levels of IgM binding to surface targets, most likely LOS (15, 60, 61). In addition, levels of C3 and C5b-9 binding to F62 PorMS11 were greater than for F62_loop1MS11loop2–8, but less so than for F62 (Fig. 5). These data suggest that C4bp bound to F62PorMS11 was indeed capable of regulating complement downward, but this was still not sufficient to overcome the initial overwhelming complement activation by IgM. Thus, in the face of high levels of IgM and kinetically overwhelming complement activation, C4bp binding alone may not be sufficient for serum resistance.

We did not succeed in constructing hybrid Por molecules that contained loop 1 of FA19 loops 2 through 8 of F62 or UU1. The apparent transformation rates with plasmids that contained these Por hybrid sequences were significantly lower than observed with pUNCH61, suggesting that recombination events that might result in generating this Por hybrid were deleterious or possibly lethal. Therefore, we can conclude that the NH2-terminal Por1A loop is required for C4bp binding, but it may not necessarily contain the entire C4bp binding region.

Using rC4bp mutant molecules as well as anti-C4bp mAbs, we have shown that the NH2-terminal SCR of C4bp contains both Por1A as well as Por1B binding regions (Fig. 7). Por1A and Por1B binding regions in SCR 1 of C4bp may differ because Por1B–C4bp, but not Por1A–C4bp, interactions can be inhibited by C4b, heparin, as well as high ionic strength (Fig. 6). Akin to Por1B–C4bp interactions, the bond between streptococcal M protein and C4bp appears to occur in close proximity to the C4b binding region in C4bp. However, the M protein–C4bp bond, unlike the entirely electrostatic C4bp–C4b bond, is governed by additional noncovalent forces (55). We have shown that loops 5 and 7 of Por1B loop in strain MS11 are both required for C4bp binding (Fig. 4). Both of these loops together may participate in forming a negatively charged patch that is required for Por1B–C4bp interactions. The overall charge of the exposed regions of loops 5 and 7 together is \(-3\), while F62 (a C4bp nonbinder) loops 5 and 7 together possess a net negative charge of \(-1.5\) (Table II).
C4bp function was also shown to be important because C4bp binding to the bacterial surface was abrogated using fAb 104. This resulted in complete killing of strain FA19, and >80% killing of MS11, both in the presence of only 10% NHS (Fig. 8 B). The pivotal role of C4bp in mediating stable serum resistance of these two strains can be gauged by the fact that both strains are otherwise fully resistant to 33% NHS (24).

The relatively slow, but sustained killing by unimpeded activation of the classical pathway is evident from the kinetics of bacterial killing when C4bp binding to the bacterial surface was inhibited by fAb 104 (Fig. 8 C). In contrast, abrogating factor H binding to strain FA19 results in almost instantaneous, although incomplete, killing (24). These observations indicate that both pathways together are critical for efficient and complete bacterial killing. The relatively slow killing by the classical pathway (alone) can be explained because C1s, the enzyme that generates the classical pathway convertases, remains bound to the organism surface and is therefore not available to cycle and again act on its substrate. In contrast, factor D, the enzyme that generates the alternative pathway convertases, is liberated after it acts on its substrate, C3bB, thus enabling recycling and efficient amplification of C3b deposition. Notably, MS11, which did not bind factor H, was also killed slowly, perhaps unexpectedly if rapid alternative pathway recruitment and efficient killing of this strain were to be expected when C4bp binding to the surface of MS11 was blocked. In an effort to explain these findings, we analyzed and compared total C3, C3b, iC3b, and factor Bb on strains MS11 and 24-1 (the latter is an SS Por1B strain, and does not bind either factor H or C4bp; reference 12). After 10 min opsonization with 10% NHS, we observed that MS11 bound 45% less C3 than 24-1, and almost all the C3b on MS11 was converted to iC3b, whereas C3b on 24-1 remained unprocessed. MS11 bound fivefold less factor Bb than 24-1. These data suggest regulation of the alternative pathway on the surface of MS11 despite its inability to bind pure factor H. A possible explanation for this phenomenon could include the ability of MS11 to bind factor H-like protein 1 (FHL-1), which is an alternatively spliced form of full-length factor H found in human serum (62, 63), and has been shown to bind M proteins of group A streptococcus and exert cofactor activity (64, 65). Other possibilities include decreased affinity of factor B for C3b on MS11, or endogenous factor H-like activity of the organism; the latter has been reported with Epstein-Barr virus (66), and merits further investigation.

Por is antigenic during natural infection (67–69) and certain evidence suggests that women with gonococcal PID and female commercial sex workers with a history of multiple gonococcal infections may be protected against repeated infection with the same serovar (70). However, other studies, involving predominantly male populations, suggest that serovar-specific protection may not be a feature of gonococcal disease (71, 72). Gonococcal Por undergoes antigenic variation in vivo over time as shown by diversity of serovars recognized in a sexual network (70, 73).

Subtle differences in Por sequence can occur even among isolates belonging to the same serovar (74). An interesting feature of nucleotide polymorphisms in the por gene is that maximum rates of nucleotide diversity occur in the putative exposed portion of Por1A loop 1 and Por1B loop 5 (75); both of these regions are critical for C4bp binding. The ability of the Por molecule to undergo sequence alterations potentially could also abrogate binding of bacterial antibodies (76, 77), in the face of retention (and perhaps an increase) in the capacity to bind complement regulators such as factor H and C4bp. This is especially likely in the case of Por1B strains, where the C4bp binding domain is formed by two noncontiguous loops and is charge dependent.

In conclusion, gonococci have several mechanisms that act cooperatively to mediate serum resistance. Factor H binds to sialic acid on LOS and mediates unstable serum resistance. Several nonsialylated gonococci can use their Por molecule to bind regulatory molecules to evade complement-mediated killing. Por1A strains bind factor H through loop 5 and C4bp possibly through loop 1, and the greater negative charge of the exposed regions of loops 5 and 7 of certain Por1B strains enable them to bind C4bp.

This work was supported by National Institutes of Health grants AI32725 and DK35081, Swedish Medical Council, Swedish National Science Research Council, Swedish Foundation for Strategic Research, and a research grant from the University Hospitals in Malmö. Dr. Ram is the recipient of the 1998–2000 American Social Health Association/Burroughs Wellcome Fund Post Doctoral Research Fellowship in Sexually Transmitted Diseases.

Submitted: 30 November 2000
Accepted: 19 December 2000

References

1. Rice, P.A., W.M. McCormack, and D.L. Kasper. 1980. Natural serum bactericidal activity against Neisseria gonorrhoeae isolates from disseminated, locally invasive, and uncomplicated disease. J. Immunol. 124:2105–2109.
2. Schumacher, G.F. 1988. Immunology of spermatozoa and cervical mucus. Hum. Reprod. 3:289–300.
3. Price, R.J., and B. Boettcher. 1979. The presence of complement in human cervical mucus and its possible relevance to infertility in women with complement-dependent sperm-immobilizing antibodies. Fertil. Steril. 32:61–66.
4. Bischof, P., D. Planas-Basset, A. Meisser, and A. Campana. 1994. Investigations on the cell type responsible for the endometrial secretion of complement component 3 (C3). Hum. Reprod. 9:1652–1659.
5. Sayers, R.A., X.J. Tao, J.T. Awwad, and K.B. Isacson. 1996. Localization of the expression of component 3 in the human endometrium by in situ hybridization. J. Clin. Endocrinol. Metab. 81:1641–1649.
6. McQuillen, D.P., S. Gulati, S. Ram, A.K. Turner, D.B. Jani, T.C. Heeren, and P.A. Rice. 1999. Complement processing and immunoglobulin binding to Neisseria gonorrhoeae determined in vitro simulates in vivo effects. J. Infect. Dis. 179:124–135.
7. Nairn, C.A., J.A. Cole, P.V. Patel, N.J. Parsons, J.E. Fox,
and H. Smith. 1988. Cytidine 5′-monophospho-N-acyetyl-
nearuminic acid or a related compound is the low Mr factor 
from human red blood cells which induces gonococcal resis-
tance to killing by human serum. J. Gen. Microbiol. 134:3295–
3306.
8. Parsons, N.J., P.V. Patel, E.L. Tan, J.R. Andrade, C.A. 
Nairn, M. Goldner, J.A. Cole, and H. Smith. 1988. Cytidine 
5′-monophospho-N-acyetyl neuraminic acid and a low mole-
cular weight factor from human blood cells induce li-
popolysaccharide alteration in gonococci when conferring 
resistance to killing by human serum. Microb. Pathog. 5:303–
309.
9. Goldner, M., C.W. Penn, S.C. Sanyal, D.R. Veale, and H. 
Smith. 1979. Phenotypically determined resistance of Neis-
seria gonorrhoeae to normal human serum: environmental fac-
tors in subcutaneous chambers in guinea pigs. J. Gen. Micro-
biol. 114:169–177.
10. Martin, P.M., P.V. Patel, N.J. Parsons, and H. Smith. 1981. 
Induction of phenotypically determined resistance of Neisseria 
gonorrhoeae to human serum by factors in human serum. J. 
Gen. Microbiol. 127:213–217.
11. Veale, D.R., C.W. Penn, and H. Smith. 1981. Factors affect-
ing the induction of phenotypically determined serum resist-
ance of Neisseria gonorrhoeae grown in media containing 
sperm or its diffusible components. J. Gen. Microbiol. 122: 
235–245.
12. Ram, S., A.K. Sharma, S.D. Simpson, S. Gulati, D.P. Mc-
Quillen, M.K. Pangburn, and P.A. Rice. 1998. A novel sialic 
acid binding site on factor H mediates serum resistance of 
sialylated Neisseria gonorrhoeae. J. Exp. Med. 187:743–752.
13. Apicella, M.A., R.E. Mandrell, M. Shero, M.E. Wilson, J.M. 
Griffiss, G.F. Brooks, C. Lammel, J.F. Breen, and P.A. Rice. 
1990. Modification by sialic acid of Neisseria gonorrhoeae li-
poooligosaccharide epitope expression in human urethral exu-
dates: an immunoelectron microscopic analysis. J. Infect. Dis. 
162:506–512.
14. O’Brien, J.P., D.L. Goldenberg, and P.A. Rice. 1983. Dis-
seminated gonococcal infection: a prospective analysis of 49 
patients and a review of pathophysiology and immune mech-
anisms. Medicine. 62:395–406.
15. Schneider, H., J.M. Griffiss, R.E. Mandrell, and G.A. Jarvis. 
1985. Elaboration of a 3.6-kilodalton lipooligosaccharide, an-
tibody against which is absent from human sera, is associated 
with serum resistance of Neisseria gonorrhoeae. Infect. Immun. 
50:672–677.
16. Brunham, R.C., F. Plummer, L. Slaney, F. Rand, and W. 
DeWitt. 1985. Correlation of auxotype and protein I type with 
expression of disease due to Neisseria gonorrhoeae. J. Infect. 
Dis. 152:339–343.
17. Cannon, J.G., T.M. Buchanan, and P.F. Sparling. 1983. 
Confirmation of association of protein I serotype of Neisseria 
gonorrhoeae with ability to cause disseminated infection. Infect. 
Immun. 40:816–819.
18. Blake, M.S., and E.C. Gotschlich. 1986. Functional and im-
munological properties of pathogenic neisserial surface pro-
teins. In Bacterial Outer Membranes as Model Systems. M. 
Inouye, editor. John Wiley, New York. 377–400.
19. Douglas, J.T., M.D. Lee, and H. Nikaoid. 1981. Protein I of 
Neisseria gonorrhoeae outer membrane is a porin. FEBS (Fed. 
Eur. Microbiol. Soc.) Microbiol. Lett. 12:305–309.
20. Sparling, P.F. 1990. Biology of Neisseria gonorrhoeae. 2nd ed. 
In Sexually Transmitted Diseases. K.K. Holmes, P.A. Mardh, 
P.F. Sparling, P.J. Wiesner, J. Cates, W.S.M. Lemon, and 
W.E. Stamm, editors. McGraw-Hill, New York. 433–449.
21. Knapp, J.S., M.R. Tam, R.C. Nowinski, K.K. Holmes, and 
E.G. Sandstrom. 1984. Serological classification of Neisseria 
gonorrhoeae with use of monoclonal antibodies to gonococcal 
outer membrane protein I. J. Infect. Dis. 150:44–48.
22. Smith, N.H., J. Maynard Smith, and B.G. Spratt. 1995. Se-
quence evolution of the porB gene of Neisseria gonorrhoeae 
and Neisseria meningitidis: evidence of positive Darwinian se-
lection. Mol. Biol. Evol. 12:363–370.
23. Ward, M.J., P.R. Lambden, and J.E. Heckels. 1992. Se-
quence analysis and relationships between meningococcal clas 
3 serotype proteins and other porins from pathogenic and non-pathogenic Neisseria species. FEMS (Fed. Eur. Mi-
crobiol. Soc.) Microbiol. Lett. 73:283–289.
24. Ram, S., D.P. McQuillen, S. Gulati, C. Elkins, M.K. Pang-
burn, and P.A. Rice. 1998. Binding of complement factor H 
to loop 5 of porin protein 1A: a molecular mechanism of se-
rum resistance of nonsialylated Neisseria gonorrhoeae. J. Exp. 
Med. 188:671–680.
25. Ingwer, I., B.H. Petersen, and G. Brooks. 1978. Serum bac-
terical action and activation of the classic and alternate 
complement pathways by Neisseria gonorrhoeae. J. Lab. Clin. 
Med. 92:211–220.
26. Facinelli, B., E. Giovanetti, P.E. Varaldo, P. Casolari, and U. 
Fabio. 1991. Antibiotic resistance in foodborne listeria. Lan-
cert. 338:1272.
27. Fujita, T., I. Gigli, and V. Nussenzweig. 1978. Human C4-
binding protein. II. Role in proteolysis of C4b by C3b-inac-
tivator. J. Exp. Med. 148:1044–1051.
28. Fujita, T., and V. Nussenzweig. 1979. The role of C4-bind-
ing protein and beta 1H in proteolysis of C4b and C3b. J. 
Exp. Med. 150:267–276.
29. Gigli, I., T. Fujita, and V. Nussenzweig. 1979. Modulation of 
the classical pathway C3 convertase by plasma proteins C4 
binding protein and C3b inactivator. Proc. Natl. Acad. Sci. 
USA. 76:6596–6600.
30. Schafstein, J., A. Ferreira, I. Gigli, and V. Nussenzweig. 
1978. Human C4-binding protein. I. Isolation and character-
ization. J. Exp. Med. 148:207–222.
31. Nagasawa, S., H. Unno, C. Ichihara, J. Koyama, and T. 
Koide. 1983. Human C4b-binding protein, C4bp. Chymo-
tryptic cleavage and location of the 48 kDa active fragment 
within C4bp. FEBS Lett. 164:135–138.
32. Dahlback, B., C.A. Smith, and H.J. Muller-Eberhard. 1983. 
Visualization of human C4b-binding protein and its com-
plexes with vitamin K-dependent protein S and complement 
protein C4b. Proc. Natl. Acad. Sci. USA. 80:3461–3465.
33. Dahlback, B., and H.J. Muller-Eberhard. 1984. Ultrastruc-
ture of C4b-binding protein fragments formed by limited 
proteolysis using chymotrypsin. J. Biol. Chem. 259:11631– 
11634.
34. Villoutreix, B.O., Y. Hardig, A. Wallqvist, D.G. Covell, P. 
Garcia de Frutos, and B. Dahlback. 1998. Structural investi-
gation of C4b-binding protein by molecular modeling: local-
ization of putative binding sites. J. Exp. Med. 188:2719–2728.
35. Hillarp, A., and B. Dahlback. 1998. Structural investi-
gation of C4b-binding protein by molecular modeling: local-
ization of putative binding sites. Proteins. 31:391–405.
36. Hissong, M., D. Kanters, T.M. Hackeng, and B.N. Bouma. 
1990. Identification of different forms of human C4b-binding 
protein lacking beta-chain and protein S binding ability. Thromb. Haemostasis. 64:245–250.
Ig-binding surface proteins of *Streptococcus pyogenes* also bind human C4b-binding protein (C4BP), a regulatory component of the complement system. *J. Immunol.* 154:375–386.

38. Berggard, K., E. Johansson, F.R. Mooi, and G. Lindahl. 1997. *Bordetella pertussis* binds the human complement regulator C4BP. *J. Immunol.* 157:3021–3029.

39. Johnsson, E., A. Thern, B. Dahlback, L.O. Heden, M.Wikstrom, and G. Lindahl. 1996. A highly variable region in members of the streptococcal M protein family binds the human complement regulator C4BP. *J. Immunol.* 156:3021–3029.

40. Carbonetti, N.H., V. Simnad, C. Elkins, and P.F. Sparring. 1990. Construction of isogenic gonococci with variable porin structure: effects on susceptibility to human serum and antibiotics. *Mol. Microbiol.* 4:1009–1018.

41. McQuillen, D.P., S. Gulati, and P.A. Rice. 1994. Co-purification of human C4b-binding protein and formation of its complex with vitamin K-dependent protein C. *Federation Proc.* 53:1009–1018.

42. Carbonetti, N.H., V.I. Simnad, H.S. Seifert, M. So, and P.F. Sparring. 1988. Genetics of protein I of *Neisseria gonorrhoeae*: construction of hybrid porins [published erratum at 86:1317]. *Proc. Natl. Acad. Sci. USA.* 85:6841–6845.

43. Swanson, J., D. Dorward, L. Lubke, and D. Kao. 1997. Porin polypeptide contributes to surface charge of gonococci. *J. Bacteriol.* 179:3541–3548.

44. Ho, S.N., H.D. Hunt, R.M. Horton, J.K. Pullen, and L.R. Pease. 1989. Site-directed mutagenesis by overlap extension using the polymerase chain reaction. *Genet. Eng.* 7:51–59.

45. Elkins, C., N.H. Carbonetti, A.J. Coimbre, C.E. Thomas, and P.F. Sparring. 1994. Cloning and expression of structural genes encoding gonococcal porin protein in non-pathogenic *Neisseria* strains. *Gene.* 138:43–50.

46. Wetzler, L.M., E.C. Gotschlich, M.S. Blake, and J.M. Koomey. 1989. The construction and characterization of *Neisseria gonorrhoeae* lacking protein III in its outer membrane. *J. Exp. Med.* 169:2199–2209.

47. Wetzler, L.M., M.S. Blake, and E.C. Gotschlich. 1988. Characterization and specificity of antibodies to protein I of *Neisseria gonorrhoeae* produced by injection with various protein I-adjuvant preparations. *J. Exp. Med.* 168:1883–1897.

48. Dahlback, B. 1983. Purification of human C4b-binding protein and formation of its complex with vitamin K-dependent protein S. *Biochem. J.* 209:847–856.

49. Matsuguchi, T., S. Okamura, T. Aso, T. Sata, and Y. Niho. 1989. Molecular cloning of the cDNA coding for proline-rich protein (PRP): identity of PRP as C4b-binding protein. *Biochem. Biophys. Res. Commun.* 165:138–144.

50. Blom, A.M., J. Webb, B.O. Villoutreix, and B. Dahlback. 1999. A cluster of positively charged amino acids in the C4BP alpha-chain is crucial for C4b binding and factor I cofactor function. *J. Biol. Chem.* 274:19237–19245.

51. Hardig, Y., A. Hillarp, and B. Dahlback. 1997. The amino-terminal module of the C4b-binding protein alpha-chain is crucial for C4b binding and factor I cofactor function. *Biochem. J.* 323:469–475.

52. Elkins, C., N.H. Carbonetti, V.A. Varela, D. Stirewalt, D.G. Klapper, and P.F. Sparring. Antibodies to N-terminal peptides of gonococcal porin are bactericidal when gonococcal lipopolsaccharide is not sialylated. *Mol. Microbiol.* 6:2617–2628.

53. Liszewski, M.K., M.K. Leung, and J.P. Atkinson. 1998. Membrane cofactor protein: importance of N- and O-glycosylation for complement regulatory function. *J. Immunol.* 161:3711–3718.

54. Elkins, C., N.H. Carbonetti, V.A. Varela, D. Stirewalt, D.G. Klapper, and P.F. Sparring. 1992. Antibodies to N-terminal peptides of gonococcal porin are bactericidal when gonococcal lipop polysaccharide is not sialylated. *Mol. Microbiol.* 6:2617–2628.

55. Blom, A.M., K. Berggard, J.H. Webb, G. Lindahl, B.O. Villoutreix, and B. Dahlback. 2000. Human C4b-binding protein has overlapping, but not identical, binding sites for C4b and streptococcal M proteins. *J. Immunol.* 164:5328–5336.

56. Ward, M.E., P.J. Watt, and A.A. Glynn. 1970. Gonococci in urethral exudates possess a virulence factor lost on subculture. *Nature.* 227:382–384.

57. Ross, J.D., M. Weir, C.K. Horn, A. Moyes, and H. Young. 1995. Gonococcal serovar patterns in Glasgow: 1990–1992. *Br. J. Biomed. Sci.* 52:87–92.

58. Moyes, A., and H. Young. 1991. Epidemiological typing of *Neisseria gonorrhoeae*: a comparative analysis of three monoclonal antibody serotyping panels. *Eur. J. Epidemiol.* 7:311–319.

59. Kohi, P.K., J.S. Knapp, H. Hofmann, K. Gruender, D. Petzoldt, M.R. Tams, and K.K. Holmes. 1986. Epidemiological analysis of *Neisseria gonorrhoeae* in the Federal Republic of Germany by auxotyping and serological classification using monoclonal antibodies. *Genitourin. Med.* 62:145–150.

60. Apicella, M.A., M.A.J. Westerink, S.A. Morse, H. Schneider, P.A. Rice, and J.M. Griffis. 1986. Bactericidal antibody response of normal human serum to the lipopolsaccharide of *Neisseria gonorrhoeae*. *J. Infect. Dis.* 153:520–526.

61. Densen, P., S. Gulati, and P.A. Rice. 1987. Specificity of antibodies against *Neisseria gonorrhoeae* that stimulate neutrophil chemotaxis. *J. Clin. Invest.* 80:78–87.

62. Zipfel, P.F., and C. Skerka. 1994. Complement factor H and related proteins: an expanding family of complement-regulatory proteins? *Immunol. Today.* 15:121–126.

63. Zipfel, P.F., T.S. Jokiranta, J. Hellwage, V. Koistinen, and S. Meni. 1999. The factor H protein family. *Immunopharmacology.* 42:53–60.

64. Johnsson, E., K. Berggard, H. Kotarsky, J. Hellwage, P.F. Zipfel, U. Sjobring, and G. Lindahl. 1998. Role of the hypervariable region in streptococcal M proteins: binding of a human complement inhibitor. *J. Immunol.* 161:4894–4901.

65. Perez-Caballero, D., S. Alberti, F. Vivanco, P. Sanchez-Corral, and S. Rodriguez de Cordoba. 2000. Assessment of the interaction of human complement regulatory proteins with group A *Streptococcus*. Identification of a high-affinity group A *Streptococcus* binding site in FHL-1. *Eur. J. Immunol.* 30:1243–1253.

66. Mold, C., B.M. Bradt, G.R. Nemerow, and N.R. Cooper. 1988. Epstein-Barr virus regulates activation and processing of the third component of complement. *J. Exp. Med.* 168:949–969.

67. McMullin, A., G. McNeillage, H. Young, and S.S. Bain. 1979. Secretory antibody response of the cervix to infection with *Neisseria gonorrhoeae*. *Br. J. Venereol.* 55:265–270.

68. O’Reilly, R.J., L. Lee, and B.G. Welch. 1976. Secretory IgA antibody responses to *Neisseria gonorrhoeae* in the genital secretions of infected females. *J. Infect. Dis.* 133:113–125.

69. Lammel, C.J., R.L. Sweet, P.A. Rice, J.S. Knapp, G.K. Scholnik, D.C. Hellbronn, and G.F. Brooks. 1985. Anti-
body-antigen specificity in the immune response to infection with Neisseria gonorrhoeae. J. Infect. Dis. 152:990–1001.

70. Plummer, F.A., J.N. Simonsen, H. Chubb, L. Slaney, J. Kimata, M. Bosire, J.O. Ndinya-Achola, and E.N. Ngugi. 1989. Epidemiologic evidence for the development of serovar-specific immunity after gonococcal infection. J. Clin. Invest. 83:1472–1476.

71. Young, H., A. Moyes, J. Ross, and A. McMillan. 1992. A serovar analysis of heterosexual gonorrhoea in Edinburgh 1986–90. Genitourin. Med. 68:16–19.

72. Fox, K.K., J.C. Thomas, D.H. Weiner, R.H. Davis, P.F. Sparling, and M.S. Cohen. 1999. Longitudinal evaluation of serovar-specific immunity to Neisseria gonorrhoeae. Am. J. Epidemiol. 149:353–358.

73. Brunham, R.C., F.A. Plummer, and R.S. Stephens. 1993. Bacterial antigenic variation, host immune response, and pathogen-host coevolution. Infect. Immun. 61:2273–2276.

74. Woods, C.R., T. Koeuth, M.M. Estabrook, and J.R. Lupski. 1996. Rapid determination of outbreak-related strains of Neisseria meningitidis by repetitive element-based polymerase chain reaction genotyping. J. Infect. Dis. 174:760–767.

75. Fudyk, T.C., I.W. Maclean, J.N. Simonsen, E.N. Njagi, J. Kimani, R.C. Brunham, and F.A. Plummer. 1999. Genetic diversity and mosaicism at the por locus of Neisseria gonorrhoeae. J. Bacteriol. 181:5591–5599.

76. Murphy, T.F., and K. Yi. 1997. Mechanisms of recurrent otitis media: importance of the immune response to bacterial surface antigens. Ann. NY Acad. Sci. 830:353–360.

77. Haase, E.M., A.A. Campagnari, J. Sarwar, M. Shero, M. Wirth, C.U. Cumming, and T.F. Murphy. 1999. Strain-specific and immunodominant surface epitopes of the P2 porin protein of nontypeable Haemophilus influenzae. Infect. Immun. 59:1278–1284.

78. Mandrell, R., M.A. Apicella, J. Boslego, R. Chung, P.A. Rice, and J.M. Griffiss. 1988. Human immune response to monoclonal antibody-defined epitopes of Neisseria gonorrhoeae lipooligosaccharides. In Gonococci and Meningococci. J.T. Poolman, H. Zanen, T. Mayer, J. Heckels, P.H. Makela, H. Smith, and C. Beuvery, editors. Kluwer Academic Publishers, Dordrecht, Netherlands. 569–574.

79. Yamasaki, R., D.E. Kerwood, H. Schneider, K.P. Quinn, J.M. Griffiss, and R.E. Mandrell. 1994. The structure of lipooligosaccharide produced by Neisseria gonorrhoeae, strain 15253, isolated from a patient with disseminated infection: evidence for a new glycosylation pathway of gonococcal lipooligosaccharide. J. Biol. Chem. 269:30345–30351.

80. Meyer, T.F., N. Mlawer, and M. So. 1982. Pilus expression in Neisseria gonorrhoeae involves chromosomal rearrangement. Cell. 30:45–52.

81. Reyn, A. 1961. Sensitivity of Neisseria gonorrhoeae to antibiotics. Br. J. Vener. Dis. 27:145–157.

82. West, S.E., and V.L. Clark. 1989. Genetic loci and linkage associations in Neisseria gonorrhoeae and Neisseria meningitidis. Clin. Microbiol. Rev. 2(Suppl):S92–S103.

83. Dudas, K.C., and M.A. Apicella. 1988. Selection and immunochemical analysis of lipooligosaccharide mutants of Neisseria gonorrhoeae. Infect. Immun. 56:499–504.

84. Babl, F.E., S. Ram, E.D. Barnett, L. Rhein, E. Carr, and E.R. Cooper. 2000. Neonatal gonococcal arthritis after negative prenatal screening and despite conjunctival prophylaxis. Pediatr. Infect. Dis. J. 19:346–349.

85. Schneider, H., J.M. Griffiss, G.D. Williams, and G.B. Pier. 1982. Immunological basis of serum resistance of Neisseria gonorrhoeae. J. Gen. Microbiol. 128:13–22.

86. Hobbs, M.M., T.M. Alcorn, R.H. Davis, W. Fischer, J.C. Thomas, I. Martin, C. Ison, P.F. Sparling, and M.S. Cohen. 1999. Molecular typing of Neisseria gonorrhoeae causing repeated infections: evolution of porin during passage within a community. J. Infect. Dis. 179:371–381.

295 Ram et al.